Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OC211
- Development stage
- Preclinical
- Lead developer
- Oncocross
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
OC211 is a Pan-KRAS inhibitor being developed by Oncocross (also known as Oncocross Australia Pty Ltd.), a South Korean biotechnology company. Discovered using the company's RAPTOR AI™ platform, OC211 is designed to target a broad spectrum of KRAS mutations (Pan-KRAS) rather than a single specific allele. KRAS mutations are among the most common drivers in human cancers, particularly in pancreatic, colorectal, and lung malignancies. By inhibiting multiple KRAS variants, OC211 aims to provide a more comprehensive therapeutic approach for KRAS-driven oncology indications. The drug is currently in the IND-enabling stage of development, undergoing in vivo studies to support future clinical trials.
02
Targets
Beyond the preview
Go deeper on OC211.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OC211.